Sign in to continue:

Thursday, February 26th, 2026

Bimergen Energy Corporation Announces $13.6 Million Public Offering and NYSE American Listing for Battery Energy Storage Projects





Bimergen Energy Corporation Announces Public Offering & NYSE American Listing

Bimergen Energy Corporation Announces Pricing of \$13.6 Million Public Offering and NYSE American Listing

Newport Beach, CA – February 20, 2026 — Bimergen Energy Corporation (“Bimergen” or the “Company”), a leading U.S.-based independent power producer specializing in utility-scale battery energy storage systems (BESS), has announced the pricing of a significant underwritten public offering and its listing on the NYSE American exchange.

Key Highlights of the Public Offering

  • Offering Structure: Bimergen is offering common stock (or pre-funded warrants in lieu of common stock) and one accompanying warrant per share or pre-funded warrant. The public offering price is set at \$4.00 per unit.
  • Gross Proceeds: The Company expects to raise approximately \$13,600,000 in gross proceeds, before deducting underwriting discounts and other offering-related expenses.
  • Warrants: Each warrant allows the holder to purchase one share of common stock at an exercise price of \$5.00 per share. Warrants are immediately exercisable upon issuance and remain so for a period of five years.
  • Over-Allotment Option: Underwriters have a 45-day option to purchase up to an additional 200,000 shares (or pre-funded warrants) and/or 200,000 additional warrants to cover over-allotments.
  • Trading and Listing: Both the shares and warrants are expected to begin trading on the NYSE American on February 20, 2026, under the symbols “BESS” and “BESSWS”, respectively.
  • Closing Date: The offering is expected to close on February 23, 2026, subject to satisfaction of customary closing conditions.

Use of Proceeds

Bimergen intends to use the net proceeds from this offering to accelerate the development of its battery energy storage projects and for general working capital purposes. This capital injection is expected to enhance the company’s ability to expand its project portfolio and strengthen its market position in the rapidly growing BESS sector.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS, BESSWS) is a U.S.-based independent power producer focused on the development, ownership, and operation of standalone battery energy storage systems. The Company’s portfolio includes utility-scale and distributed storage projects designed to improve grid reliability, facilitate renewable energy integration, and provide flexible energy solutions. Bimergen manages the full project lifecycle, including site selection, permitting, engineering, procurement, construction, and operations, with assets spanning multiple power markets across the United States.

Important Shareholder Considerations & Potential Price Sensitivity

  • Dilution Risk: The issuance of new shares (and potential exercise of warrants) will result in dilution for existing shareholders. Investors should consider the impact of the increased share count on future earnings per share and voting power.
  • Capital Allocation: The Company’s stated use of proceeds for project development and working capital suggests a focus on growth, which, if executed well, could drive long-term value. However, investors should monitor execution risks and timelines.
  • Market Listing: The commencement of trading on the NYSE American may increase liquidity and visibility for Bimergen’s securities, which could potentially attract new institutional and retail investors.
  • Warrant Terms: The five-year term and immediate exercisability of the warrants may create additional supply of shares in the market over time, which can impact price dynamics.
  • Forward-Looking Statements: The Company’s statements regarding expansion and project development are subject to substantial risks and uncertainties. Shareholders are encouraged to review the “Risk Factors” section in the Company’s final prospectus for more information.

Offering Details

Book-Running Manager: ThinkEquity is acting as the sole book-running manager for the offering.
Registration Statement: The offering is being made pursuant to a registration statement on Form S-1 (File #333-280668), which became effective on January 29, 2026.

Copies of the final prospectus, when available, can be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, NY 10004, or via the SEC’s website at www.sec.gov.

Contact Information

Investor Relations:
Dave Gentry
RedChip Companies Inc.
Phone: 1-407-644-4256 or 1-800-REDCHIP (733-2447)
Email: [email protected]


Disclaimer: This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The information herein contains forward-looking statements which are subject to risks and uncertainties. Investors should carefully review the final prospectus and consult their financial advisor before making any investment decisions. Bimergen Energy Corporation undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances.




View Bimergen Energy Corp Historical chart here



Bank of Marin (BMRC) 2026 Financial Results, Strategic Initiatives, and XBRL Filings Overview

Bank of Marin Bancorp 8-K: Detailed Investor Report – February 2026 Bank of Marin Bancorp 8-K Filing: Key Investor Insights from February 2026 Executive Summary Bank of Marin Bancorp (Nasdaq: BMRC), headquartered in Novato,...

$300 Million Revolving Credit Agreement: Definitions, Terms, and Lender Information for Energy & Transportation (2026)

Pinnacle West Capital Corporation: Detailed Investor Update on New Credit Agreements Pinnacle West Capital Corporation Announces Major Five-Year Credit Facility Amendments Key Points for Investors Pinnacle West Capital Corporation (“Pinnacle West”) has entered into...

Corcept Therapeutics Provides Update on Patent Dispute With Teva Pharmaceuticals Over Korlym Generic – Court Rules No Infringement

Key Points from the Report Federal Court Ruling: The United States Court of Appeals for the Federal Circuit has upheld a previous verdict that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does...

   Ad